- Histogen Inc (NASDAQ:HSTO) has decided to suspend the development of the HST 001 program after taking into consideration the results from the Phase 1b/2a trial in androgenic alopecia (male pattern baldness).
- It said while HST 001 demonstrated a favorable safety and tolerability profile, the development resources required to potentially achieve an acceptable efficacy threshold are substantial in terms of cost and time.
- In February, HST-001 did not achieve statistical significance at week 26 compared to the placebo on change from baseline in total hairs in the target area.
- The company said it is on track to initiate Phase 1/2 trial for HST 003 this month for cartilage regeneration in the knee.
- The company also initiated an investigational new drug application (IND) enabling activities for HST 004, a CCM solution intended to be administered through an intradiscal injection for spinal disc repair. The filing of an IND is expected in the second half of 2022.
- Last month, the company and its partner Amerimmune completed enrollment of the Phase 1 study of emricasan to treat mild-symptomatic COVID-19 patients.
- 13 patients have been enrolled versus the initially targeted 40 patients.
- To date, there have been no reports of serious adverse events, and top-line safety, biomarker, and patient-reported outcomes data are expected to be available in June.
- Price Action: HSTO shares down 2.9% at $0.99 during the market session on the last check Thursday.
NIO Q3 Adj. EPADS $(0.30) Misses $(0.16) Estimate, Sales $1.83B Beat $1.79B Estimate
NIO (NYSE:NIO) reported quarterly adjusted losses per ADS of $(0.30) per share which missed the analyst consensus estimate of $(0.16) by 87.5 percent. This is a 400 percent decrease over losses of $(0.06) per ADS from
